Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome

Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the first patient has been dosed in its Phase 1/2 UNITE study evaluating MZ-1866, an investigational gene therapy for the treatment of Pitt Hopkins syndrome.